experts Call for Rebranding of “Artificial Tears” as “Lubricating Drops” to Improve Patient Understanding
A shift in terminology could lead to more informed treatment decisions for dry eye disease, according to a recent proposal.
The common term “artificial tears” may be misleading patients and hindering optimal care for dry eye disease, leading experts to advocate for a change to “lubricating drops.” This seemingly small adjustment, outlined in a letter to the editor published in The Ocular Surface, could have significant implications for both patient expectations and clinical practice.
Why the Change is Proposed
Experts argue the term “artificial tears” inaccurately suggests these over-the-counter drops replicate the complex biological functions of natural tears – immunological, nutritional, and regenerative – which they do not. This misrepresentation can lead patients to delay seeking more effective, prescription-based treatments for dry eye disease. The core issue is a disconnect between what the name implies and what the product actually does.
Who is Advocating for the Change?
The proposal originates from a group of ophthalmologists and researchers who published their concerns in The Ocular Surface. While no specific individuals are named as leading the charge, the letter represents a consensus view within a segment of the eye care community. The call for change extends to optometrists and ophthalmologists, requiring a broad, collaborative effort.
What Would “Lubricating Drops” Achieve?
Switching to “lubricating drops” aims to clarify the product’s function: symptom relief through lubrication. This more accurate terminology would help patients understand these drops are not a cure for dry eye, but a tool to manage discomfort. For providers, it would streamline communication and prevent time spent correcting patient misconceptions, allowing for more efficient clinical decision-making.It would also allow for a more unified categorization of products, including “rewetting drops” for contact lens wearers.
How Could This Change Be Implemented?
Implementing the change requires a multi-faceted approach. First,consensus-building within the ophthalmic community is essential. Following this, advocates propose engaging with the Food and Drug Management (FDA) to discuss re-evaluating guidance surrounding these products. The authors specifically suggest an FDA workshop to debate the issue and establish new industry standards.Regulatory changes would then be necessary to officially adopt the new terminology.
What is the Current Status and How Did it End (or is Ending)?
As of November 2023,the proposal remains in the discussion phase. There has been no official action taken by the FDA or widespread adoption of “lubricating drops” by manufacturers. The letter to the editor served as a catalyst for conversation, raising awareness of the potential benefits of a terminology shift. The outcome hinges on continued advocacy from eye care professionals and a willingness from the FDA to consider a reclassification. The process is ongoing, with the hope of improved patient understanding and care in the future.
